drugset

drugset / Trial / NCT03001609

Study to Investigate the Absorption, Metabolism and Excretion of [14C] AC0010 in Patients With Advanced NSCLC

NCT03001609 ↗

Phase 1 Completed 7 enrolled Hangzhou ACEA Pharmaceutical Research Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate Pharmacokinetics parameters of a single dose \[14C\] AC0010 in male Patients With Advanced NSCLC.

Timeline

Start: 2016-11
Primary completion: 2017-08
Completion: 2017-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abivertinib	Small molecule	200 mg	Oral

Indications